The XXVI-th National Congress of Hepatology
Fundatia Acad. M. VOICULESCU
8.30 - 9.00: Opening Ceremony In Memoriam Prof. Dr. Mihai Voiculescu
09.00 - 10.40 Session 1 - HBV infection
Chairmens: Patrick Marcellin, George Papatheodoridis, Geoffrey Dusheiko
|09.00 - 09.20||Geoffrey Dusheiko||An update of HBV infection|
|09.20 - 09.40||G. Papatheodoridis||Nucleos(t)ide analogues withdrawal:
in whom, when and why ?
|09.40 - 10.00||Laurentiu Micu||Management of HBV infection in pregnancy|
|10.00 - 10.20||Patrick Marcellin||Advantages of combination of PEG IFN + TDF versus monotherapy|
|10.20 - 10.40||Round table: Conclusions and recommendation|
10.40 - 11.40 Symposium GILEAD
11.40 - 12.00 Symposium PROTON
12.00 - 13.30 Session 2 - HCV infection I
Chairmens: Peter Ferenci, Vlad Ratziu, Lawrence Serfaty
|12.00 - 12.20||V.Ratziu||HCV eradication benefits|
|12.20 - 12.40||K. Antonov
|What is happened with the liver disease after the
eradication of HCV infection?
|12.40 - 13.00||L. Serfaty||Retreating patients with DAA Failure|
|13.00 - 13.20||P. Ferenci||Treatment of HCV - is the job done?|
|13.20 - 13.30||Round table: Conclusions|
13.30 - 14.30 Simposium ABBVIE
14.30 - 15.30 Lunch Break
15.30 - 16.00 Patrizia Burra : The management of HCV infection post-transplantation
16.00 - 16.20 Mariana Mihaila: The management of HBV infection post-transplantation
16.20 - 18.15 Session 3 - HCV infection II
Chairmens: Anca Trifan, Oliviu Pascu, Laura Iliescu
|16.20 - 16.40||Laura Iliescu||Management of IFN-free therapy in patients with HCV liver cirrhosis and co-morbidities|
|16.40 - 17.00||Anca Trifan||What happens after SVR in HCV patients with cirrhosis|
|17.00 - 17.20||Cristina Cijevschi, C. Mihai||HCV infection and the risk of liver cancer in DAA era|
|17.20 - 17.40||Simona Ruta||Who might still benefit from the interferon-based therapies
in chronic hepatitis C in 2016
|17.40 - 18.00||Gabriela Oprisan||Patterns of HCV mutations|
|18.00 - 18.15||Round table: Conclusions|
08.30 - 10.00 Session 4 – Liver fibrosis
Chairmens: Dan Dumitrascu, Carol Stanciu, Manuela Neuman
|8.30 - 8.50||O. Orasan, D. Dumitrascu||Non-invasive evaluation of liver fibrosis|
|08.50 - 09.10||Carol Stanciu, Camelia Cojocariu||The place and the importance of the liver biopsy in evaluation of liver fibrosis|
|09.10 - 09.30||Manuela Neuman||NAFLD and moderate alcohol consumption|
|09.30 - 09.50||Azra Husic Selimovic||Actual antifibrotic therapies in patients with chronic liver disease|
|09.50 - 10.10||I. Copaci||Coagulation disorders in patients with advanced fibrosis/cirrhosis: the ups and downs|
|10.10 - 10.30||Round table: Conclusions|
10.30 - 11.00 Coffee Break
11.00 - 12.40 Session 5 - NASH
Chairmens: Arun Sanyal, Vlad Ratziu, Carmen Fierbinteanu-Braticevici
|11.00 - 11.20||Carmen
Fierbinteanu - Bratisevici
|Who are the patients at risk of NAFLD/NASH
progression and complications ?
|11.20 - 11.40||Arun Sanyal||Emerging trends treatment of nonalcoholic steatohepatitis|
|11.40 - 12.00||R. Pais||Risk of liver cancer in NASH|
|12.00 - 12.20||V. Ratziu||Innovative new therapy in NASH|
|12.20 - 12.40||Round table: Conclusions|
12.40 - 13.40 Simposium Alfa Wassermann
13.40 - 14.15 Simposium Merz
14.15 - 15.30 Lunch Break
15.30 - 18.00 Session 6 - Cirrhosis and its complications
Chairmens: Monica Acalovschi, Maxim Mallete
|15.30 - 15.50||Monica Acalovschi||Who needs HCC surveillance and how to do it|
|15.50 - 16.10||M. Munteanu||Awareness of the severity of liver disease and access to interferon-free regimen treatment of chronic hepatitis C - a French tertiary center and Romanian experiences|
|16.10 - 16.30||M. Mallete||New perspectives concerning the prevention of variceal bleeding|
|16.30 - 16.50||C. Achim|
|16.50 - 17.10||M. Toma||Radiointerventional treatment of inoperable HCC|
|17.10 - 17.30||M. Grigorie||Surgical treatment of HCC|
|17.30 - 17.50||E. Mindrut||Current treatment strategies in HCC in 2016|
|17.50 - 18.00||Round table: Conclusions|
09.00 - 10.40 Session 7 - Autoimmune liver diseases
Chairmens: Coman Tanasescu, Simona Valean, Manuela Neuman
|09.00 - 09.10||Simona Valean||Introduction|
|09.10 - 09.30||Anca Trifan, Ana Maria Sangeap||Autoimmune hepatitis clinical presentation and diagnosis|
|09.30 - 09.50||Doinita Crisan||Autoimmune hepatitis: histological aspects and their contribution to diagnosis|
|09.50 - 10.05||Coman Tanasescu||Biological therapy of autoimmune hepatitis – between theory and practice|
|10.05-10.25||Manuela Neuman||sRank1-inhibitor- induced autoimmune hepatitis|
|10.25 - 10.40||Round table: Conclusions|
10.40 - 11.00 Coffee Break
11.00 - 13.00 Session 8 - Liver transplantation
Chairmens: Antonio Rampoldi, Irinel Popescu, Dana Tomescu
|11.00 - 11.20||V. Zota, Carmen Pantis||Management of marginal liver donors, a new challenge for transplantation medicine|
|11.20 - 11.40||Mariana Mihaila||The liver transplant ABO incompatibility|
|11.40 - 12.00||Antonio Rampoldi||Advanced application of TIPS: portal cavernoma; portal hypertension in OLT|
|12.00 - 12.20||Dana Tomescu||Living related liver transplant for acute liver failure|
|12.20 - 12.40||Irinel Popescu||Liver Transplant in Romania in 2016|
|12.40 - 13.00||Round table: Conclusions|
13.00 Closing remarks
It's a privilege for us to invite you to Romanian Association for the Study of Liver (RASL) annual meeting, which remains the premier liver meeting. We proudly celebrate this year the 26th Congress of RASL together with our friends from France (the 5th French-Romanian Symposium) and from Balkan (7th Postgraduate Balkan Hepatology Course).
The meeting is focusing on highly specialized topics in liver diseases. Attendees have the unique opportunity to meet the leader professors in the field of Hepatology. Moreover, young colleagues who share same interests, will have the opportunity to networking the with the faculty coming from Europe and North America . Our program is designed for all professionals involved with the study, treatment, and management of liver disease. It will feature a comprehensive review of evidence-based approaches to the diagnosis and management of a wide range of hepatic disorders. New changes and improvements have been introduced in 2015, that will allow us more time to present the curriculum developed by the scientific committee. Our flexible, interesting agenda is based on the news in Hepatology and attendees' requests. The program brings still unsolved questions:
- Viral hepatitis B (HBV) treatment is now considered indefinite. How we can better monitor patients and prevent long term complications of virus and treatment effects?
- There are many DAA available to eradicate hepatitis C virus (HCV). Which are the best current HCV treatment strategies. What to do with "cured" patients after the virus was eradicated?
- Liver cancer is one of the most frequent and lethal digestive cancer. Who needs liver cancer surveillance and how to do it? We need to optimize the management of liver cancer and to have standard of care for liver cancer. Targeted liver cancer therapy is now possible.
- Optimizing diagnosis and treatment of alcoholic and non-alcoholic liver disease is one of the most attractive topic today. What are the therapeutic interventions?
- We need to known the best practice in fibrosis evaluation and its clinical and therapeutic consequences. The non-invasive evaluation of fibrosis is one of the most important subjects in Liver Congress.
- There are new strategies that focus on stratifying risk and individualizing care for portal hypertension, managing hepatic encephalopathy and fluid overload in cirrhosis, possible therapeutics for patients with cirrhosis of the liver.
The practice of liver disease has matured rapidly, and innovations in science have had an enormous impact on the ability to diagnose and treat our patients. The major goal of this new curriculum is to offer an up-to-date on the management of patients with liver disease, while also providing insight into patho-physiologic concepts in the specific disease.
This is an ideal continuing education opportunity for practicing hepatologists, gastroenterologists, infection disease specialist and other practitioners wanting to augment their clinical knowledge. In addition, the course will appeal to researchers, trainees, nurses and pharmacologists who want to enhance their knowledge of liver diseases.
We anticipate that new elements of The Romanian-French Meeting and 7th Balkan Hepatology Course in 2016 will engage both practicing physicians, scientists and industry with ample programming choices. The organizers hope that at the end of the Congress and Postgraduate Course the participants will enhance not only their knowledge but how to practice more efficient.
Presidents of the Congress
Anca Trifan M.D.
Manuela Neuman M.D.
Monica Acalovschi M.D.
Stephanos Hadziyannis M.D.
Patrick Marcellin M.D.
Azra Husic Selimovic